Introduction {#Sec1}
============

Tuberculosis (TB) is a chronic infectious disease caused by *Mycobacterium tuberculosis* and is one of the top 10 global causes of death caused by a single infectious agent. According to a WHO report, TB caused 1.3 million deaths in 2018, and 10.0 million people are estimated to have developed TB in 2017. More than 90% of the infection cases occur in developing countries such as India (27%), China (9%), and Indonesia (8%) (WHO [@CR60]). In addition, the high incidence of HIV/TB co-infection, together with the emergence of multi-drug-resistant *M. tuberculosis* strains, is now believed to pose a huge threat to global human health (Mesfin et al. [@CR35]). Currently, anti-TB treatment is largely limited to drugs which were developed decades ago like ethionamide (1960), ethambutol (1961), capreomycin (1963), and rifampicin (1963) (Liu et al. [@CR32]). Despite the recent approval of two new drugs, bedaquiline (2012) (Andries et al. [@CR2]) and delamanid (2014) (Matsumoto et al. [@CR33]), there is still a rising need for novel anti-TB drugs due to the fact that acquired resistance has been observed in therapy process (Bloemberg et al. [@CR5]). Anti-TB drug discovery has not kept pace with increasing levels of drug resistance (Dheda et al. [@CR14]) and efforts are being made to discover such compounds.

Natural products (NPs) are small molecules evolutionary selected by nature (in some sense pre-validated for bioactivity) that often display unique chemical diversity (Cragg and Newman [@CR11]; Liu et al. [@CR29]; Newman and Cragg [@CR39]). Seven out of 11 currently used nature-derived TB drugs were either isolated from microbes or semi-synthesized from microbial natural products (Liu et al. [@CR32]), and almost 60% of the antibiotics that are currently used in clinic for TB treatment are produced by *Streptomyces* (Ashforth et al. [@CR3]). Driven by substantial overlap in the structures of newly discovered anti-TB compounds from *Streptomyces*, researchers have begun to focus on rare actinobacteria, which are viewed as vast potential reservoirs of novel NPs (Dhakal et al. [@CR13]). Microbes from extreme environments such as deep-sea sediments and hot springs harbor unique secondary metabolite biosynthesis genes and possess high potentials of chemical space (Jiang et al. [@CR22]; Okoro et al. [@CR41]; Pettit [@CR43]). Microorganisms from extreme environments have received extensive research attention because they can yield basic biological insights *via* comparisons of more widespread physiological processes versus the unique physiological mechanisms that allow them to exist and even thrive in extreme conditions (Meklat et al. [@CR34]). These microorganisms are known to produce many structurally diverse NPs (Katz and Baltz [@CR24]).

In the course of our previous screening work seeking for anti-TB NPs from microorganisms, we have developed a screening assay that tests the compound's growth inhibitory activity against Bacillus Calmette-Guérin (BCG), which is an attenuated strain of the bovine tuberculosis bacillus *M. bovis* (Ashforth et al. [@CR3]; Huang et al. [@CR18]; Liu et al. [@CR30]; Wang et al. [@CR59]). Here, we examined the biodiversity of rare actinobacteria sampled from extreme environments in the Xinjiang region and investigated their anti-BCG natural products. Seventeen samples were collected from different sites from diverse ecological systems in Xinjiang, resulting in isolation of 260 actinomycete strains. Phylogeny analysis of 40 strains with distinct morphological features indicated the presence of strains from 8 genera, highlighting the biodiversity of the rare actinobacteria present in these locations. Strain XJ31 of the *Nocardia* genus was examined in detail and a systematic natural product profiling and isolation program led to the purification and structural elucidation of 14 compounds from XJ31 based on HR-ESI-MS, 1D NMR, and 2D NMR techniques. Twelve of these compounds are oligopeptides (siderophores), including nocardimicin B (**1**), nocardimicin D (**2**), nocardimicin F (**3**), and nocardimicins J-R (**4**-**12**), while the remaining two are the benz\[α\]anthraquinones brasiliquinones D (**13**) and E (**14**). Notably, 10 out of the 14 compounds described in this study have not been reported previously (**4**-**12** and **14**), and the two benz\[α\]anthraquinones showed good activity against BCG (MICs = 25 μM) in bioassays.

Materials and methods {#Sec2}
=====================

General experimental procedures {#Sec3}
-------------------------------

NMR spectra were obtained on a Bruker Avance DRX500 spectrometer (Bruker, Billerica, USA). Chemical shifts were calibrated internally against residual solvent signals (Pyridine-*d*~*5*~: *δ*~C~ 123.87/135.91/150.35, *δ*~H~ 7.22/7.58/8.74; CD~3~OD: *δ*~C~ 49.0, *δ*~H~ 3.31/4.87). HR-ESI-MS analysis was conducted on a Bruker micrOTOF mass spectrometer. Resin HP-20 (Diaion, Osaki, Japan), Sephadex LH-20 (GE Healthcare BioSciences AB, Marlborough, USA), and ODS-A (YMC, Wesel, Germany) were used for isolation. HPLC analysis was performed using an Agilent 1100 Series HPLC; data analysis was conducted using ChemStation Rev.B.02.01 software.

Isolation of rare actinobacteria by selective isolation methods {#Sec4}
---------------------------------------------------------------

The actinomycete-selective isolation media (Table [S1](#MOESM1){ref-type="media"}) used in the present study comprised HV agar (Hayakawa and Nonomura [@CR17]), SM3 agar (Tan et al. [@CR53]), MOPS agar, Starch-Casein-Nitrate agar (Küster and Williams [@CR26]), and AV (arginine vitamins) agar (Nonomura [@CR40]). Soil samples were pretreated at 80 °C for 1 h. One gram of soil sample collected from different locations was then suspended in 10 mL of sterile water individually. After vortexing, the supernatant was spread onto isolation media and grown for 7−14 days at 28 °C. Visible colonies were then transferred onto ISP2 agar (Shirling and Gottlieb [@CR49]) for purification and long-term storage.

Microbial strain culture and identification {#Sec5}
-------------------------------------------

Strain XJ31 was isolated from a soil sample collected from Xinjiang, China, in July 2011, and maintained on ISP2 agar (4% glucose, 10% malt extract, 4% yeast extract, 2% agar, pH 7.0) at 28 °C. The identification of strain XJ31 was performed based on both morphological and 16S rDNA phylogenetic analysis. Mature aerial mycelium and substrate mycelium pigmentation were recorded on ISP2 agar media after incubation at 28 °C for 7 days. Genomic DNA extractions were carried out following a standard CTAB procedure as described in Practical Streptomyces Genetics (Kieser et al. [@CR25]). A pair of primers (27F: 5′-GAGAGTTTGATCCTGGCTCAG-3′; 1492R: 5′-CTACGGCTACCTTGTTACGA-3′) was used to amplify the 16S rDNA. PCR (25 μL volume in total: contains 2.5 μL 10 × buffer (Takara), 2 μL 2.5 nM dNTP (Takara), 0.5 μL of each 20 μM primer, 1.5 U rTaq polymerase (Takara), and 1 μL DNA template) was performed on a Takara PCR Thermal Cycler with the initial denaturation at 95 °C for 5 min, followed by 28 cycles of denaturation (95 °C, 30 sec), annealing (55 °C, 30 sec) and elongation (72 °C, 1 min 30 s), and a final elongation at 72 °C for 10 min. Multiple sequence alignment of 16S rRNA gene with the related species was carried out using ClustalW (Thompson et al. [@CR54]). A phylogenetic tree was constructed using the neighbor-joining method (Saitou and Nei [@CR47]) by MEGA 7.0 (Tamura et al. [@CR52]). Bootstrap values were calculated by resampling 1000 replicates (Felsenstein [@CR15]).

Strain XJ31 has been deposited at the China General Microbiological Culture Collection Center (accession number 4.7298). The nucleotide sequences of the 16S rRNA gene have been deposited with NCBI (accession number KT951165).

Fermentation, extraction, and isolation {#Sec6}
---------------------------------------

Twenty-one different actinomycete fermentation media (Table [S2](#MOESM1){ref-type="media"}) were used for the small-scale fermentation of strain XJ31. Prior to fermentation, strain XJ31 was cultivated on an ISP2 agar plate at 28 °C for 5 days. Each 250-mL Erlenmeyer flask containing 40 mL of fermentation broth (5% of inoculum) was inoculated with a small portion (1 cm^2^) of mycelium on agar and grew for 7 days at 28 °C with shaking at 220 rpm. The fermentation broth was then extracted using 40 mL of a water/EtOAc (v/v: 1:1) solvent system, and the crude extracts were analyzed by HPLC-UV analysis with an Eclipse XDB-C8, 5 μm column (4.6 × 150 mm, Agilent) using a gradient elution: 5−99% ACN/H~2~O for 30 min, 99% ACN for 10 min.

Large-scale fermentation was performed using a two-step seed culture process. The primary seed culture used a 250-mL Erlenmeyer flask containing 40 mL of ISP2 medium which was inoculated with mycelium of XJ31 grown on ISP2 agar and incubated at 28 °C, at 220 rpm for 5 days. Aliquots (12 mL) of the primary seed culture were used to inoculate four 1-L Erlenmeyer flasks, each containing 250 mL of ISP2 broth to serve as a secondary seed culture. After incubation at 28 °C, 220 rpm for 5 days, aliquots (15 mL) of the secondary seed cultures were aseptically transferred into 80 1-L Erlenmeyer flasks each containing 250 mL of Noc05 fermentation medium (starch 1.0%, glucose 1.0%, glycerol 1.0%, corn steep 0.25%, peptone 0.5%, yeast extract 0.2%, NaNO~3~ 0.1%, CaCO~3~ 0.3%, pH natural), and fermentation was carried out at 28 °C, 220 rpm for 7 days. Fermentation broth was combined and centrifuged at 8000 rpm for 10 min to separate supernatant and mycelia cake. Supernatant was extracted three times with 20 L of the aforementioned water/EtOAc solvent system and the organic layer was combined and concentrated by rotary evaporation. The crude extract was initially fractionated using an ODS-MPLC (35 × 2.2 cm) using a stepwise gradient of 5−100% MeOH/H~2~O for 70 min and 100% MeOH for 40 min, yielding five fractions (fraction 1\~5).

Fraction 5 was dried by rotary evaporation yielding 90 mg crude extract, which was then fractionated on a Sephadex LH-20 column (50 × 3 cm) in MeOH yielding six subfractions (fraction 5-1\~5-6). Fraction 5-3 (5 mg) was further purified by reverse phase HPLC (ZORBAX RX-C8 9.4 × 250 mm, 5 μm column, 2.5 mL/min, gradient elution: 45% ACN/H~2~O for 30 min and 99% ACN for 10 min) yielding **13** (*t*~R~ = 19.11 min; 1.0 mg) and **14** (*t*~R~ = 28.38 min; 2.5 mg).

The mycelia cake was extracted three times with 1 L acetone and the organic layer was combined and concentrated by rotary evaporation. The crude extract (2.3 g) was passed through an ODS-MPLC (35 × 2.2 cm) developed by a stepwise gradient of 70−90% MeOH/H~2~O for 45 min, 90−100% MeOH for 30 min, 100% MeOH for 45 min, 100−90% MeOH/CH~2~Cl~2~ for 30 min, 90−80% MeOH/CH~2~Cl~2~ for 20 min, 80% MeOH/CH~2~Cl~2~ for 40 min, and 100% isopropanol for 50 min yielding seven fractions (fraction 6\~12). LC-MS analysis and UV absorption characteristics revealed that fraction 8 contained a series of siderophore-type compounds. However, the purification was challenged due to the peak overlapping on HPLC as well as the different ion-chelating forms of siderophores. Thus, chelation with GaBr~3~ of fraction 8 solution was applied in order to stabilize all compounds in their Ga^3+^ chelation form for feasible purification. Fraction 8 (1.2 g) was dissolved in 400 mL MeOH and mixed with 2.5 g GaBr~3~ (dissolved in 6 mL MeOH) at room temperature for 1 h to yield fraction 8a. Fraction 8a was then fractionated by ODS-MPLC (35 × 2.2 cm) developed by a stepwise gradient of 85−100% MeOH/H~2~O for 60 min, 100% MeOH for 30 min, 100−90% MeOH/CH~2~Cl~2~ for 30 min, 90−80% MeOH/CH~2~Cl~2~ for 20 min, and 100% isopropanol for 30 min to yield subfractions (fractions 8a-1\~8a-7). Fraction 8a-3 (126 mg) was further fractionated on reverse phase HPLC (ZORBAX RX-C~8~ 9.4 × 250 mm, 5 μm column, 2.5 mL/min, isocratic elution with 68% ACN/H~2~O for 52 min) to give **1a** (*t*~R~ = 19.1 min; 13.7 mg), **4a** (*t*~R~ = 23.2 min; 8.7 mg), and **5a** (*t*~R~ = 28.4 min; 13.7 mg). Fraction 8a-4 (83.5 mg) was fractionated on reverse phase HPLC (ZORBAX RX-C~8~ 9.4 × 250 mm, 5 μm column, 2.5 mL/min, isocratic elution with 63% ACN/H~2~O for 52 min) to give **2a** (*t*~R~ = 35.8 min; 10.5 mg), **6a** (*t*~R~ = 40.0 min; 5.5 mg), and **7a** (*t*~R~ = 51.0 min; 4.7 mg). Fraction 8a-5 (173 mg) was fractionated on reverse phase HPLC (ZORBAX RX-C~3~ 9.4 × 250 mm, 5 μm column, 2.5 mL/min, eluted with 70% ACN/H~2~O for 36 min and 70−90% ACN/H~2~O for 9 min) to give **3a** (*t*~R~ = 25.4 min; 14.0 mg), **8a** (*t*~R~ = 30.5 min; 9.0 mg), and **9a** (*t*~R~ = 36.1 min; 5.7 mg). Fraction 8a-6 (300 mg) was first passed through a Sephadex LH-20 column developed by MeOH to yield four fractions (fraction 8a-6-1\~8a-6-4). Fraction 8a-6-3 which contained the siderophores was further fractionated by reverse phase HPLC (ZORBAX RX-C~8~ 9.4 × 250 mm, 5 μm column, 2.5 mL/min, isocratic elution with 63% ACN/H~2~O for 52 min) to obtain **10a** (*t*~R~ = 31.2 min; 3.0 mg), **11a** (*t*~R~ = 35.9 min; 2.8 mg), and **12a** (*t*~R~ = 41.6 min; 1.8 mg).

Anti-BCG bioassay {#Sec7}
-----------------

The anti-BCG bioactivity of isolated compounds was tested following the previously described procedure (Wang et al. [@CR59]; Wayne [@CR63]). The assay was performed with a strain of *Mycobacterium bovis* (BCG Pasteur 1173P2) containing a constitutive green fluorescent protein (GFP) expression vector (pUV3583c-GFP) using direct readout of fluorescence as a measure of bacterial growth, as described previously (Wang et al. [@CR57], [@CR58]). The BCG strain was pre-cultivated to mid-log phase (7 days) at 37 °C in Middlebrook 7H9 broth (40 mL; Difco) supplemented with 10% OADC enrichment (Becton Dickinson), 0.05% Tween-80, and 0.2% glycerol and then diluted to an OD600 of 0.025 with broth. A twofold serial dilution of each compound to be tested (4000 to 31.3 μg/mL in DMSO) was prepared and an aliquot of each dilution (2 μL) was added to a 96-well flat-bottom microtiter plate (Greiner). Isoniazid was used as the positive control and DMSO as the negative control. An aliquot (78 μL) of the BCG-GFP bacterial suspension was then added to each well (to give final compound concentrations of 100 to 0.78 μg/mL in 2.5% DMSO) and the plate was incubated at 37 °C for 3 days. Mycobacterial growth was determined by measuring GFP-fluorescence using an EnVision 2103 Multilabel Plate Reader (Perkin-Elmer Life Sciences) with excitation at 485 nm and emission at 535 nm. All the experiments were performed in triplicate. MIC was defined as the minimum concentration that inhibited more than 90% of bacteria growth.

Results {#Sec8}
=======

Isolation of rare actinomycete by selective isolation methods {#Sec9}
-------------------------------------------------------------

We have isolated more than 600 actinobacterial strains from soil samples collected from 17 sampling sites in Xinjiang region (Fig. [1A](#Fig1){ref-type="fig"} and Table [S3](#MOESM1){ref-type="media"}) using the five selective isolation media. All strains were de-replicated based on phenotype and morphology, and 260 actinobacteria strains were selected to build the culture library (data not shown). These actinobacteria strains isolated from Xinjiang environment exhibited a high degree of phenotypic diversity (Fig. [1B](#Fig1){ref-type="fig"}) and many of them showed distinct phenotypes from *Streptomyces*. The presence of these rare actinobacteria emphasizes the unique microbial diversity characteristic of the Xinjiang area and supports the idea of extreme diverse environment being an important resource for new chemical compounds. The phylogeny of these taxa was further investigated based on 16S rRNA gene sequence analysis: the 40 strains with distinct morphologies were subjected to systematic taxonomy analysis and were found to belong to 8 genera, including *Micromonospora*, *Nocardia*, *Modestobacter*, *Glycomyces*, *Prauserella*, *Haloactinopolyspora*, *Plantactinospora*, *Polyangium*, and *Acinetobacter* (Fig. [1B](#Fig1){ref-type="fig"} and Fig. [S15](#MOESM1){ref-type="media"}). This diversified phylogeny composition underscores that the *Actinobacteria* of Xinjiang have great potential as a potential source of novel natural products. Among these 260 actinobacteria strains, strain XJ31 was identified as a new *Nocardia* species according to 16S rRNA phylogenetic analysis. Moreover, the HPLC profile of XJ31 exhibits high compound diversity and abundance; thus, strain XJ31 was chosen for detailed characterization.Fig. 1A survey of rare actinobacteria and anti-BCG compounds from Xinjiang region. (A) The sampling sites in Xinjiang region (Table [S3](#MOESM1){ref-type="media"}). (B) Colony characteristics and overview of the rare actinomycete genera (assessed using 16S rRNA gene sequences) based on selected isolation of microbes. (C) Colony characteristics of the XJ31 strain, and the isolated anti-TB active compound brasiliquinone E

Characterization of strain XJ31 and structural elucidation and biological activities evaluation of its natural product compounds {#Sec10}
--------------------------------------------------------------------------------------------------------------------------------

After incubation at 28 °C for 7 days, strain XJ31 formed a puce-colored colony on ISP2 plates (Fig. [1C](#Fig1){ref-type="fig"}). No diffusible pigments were produced. Phylogenetic analysis of the strain's 16S rRNA gene sequence (Fig. [2](#Fig2){ref-type="fig"}) demonstrated that strain XJ31 belongs to the genus *Nocardia*, exhibiting closest similarity to the 16S rRNA gene sequence of *N. sungurluensi*s (97.94%) (Camas et al. [@CR8]).Fig. 2Neighbor-joining phylogenetic tree based on 16S rRNA gene sequences from XJ31 and related species constructed using MEGA 7.0, with *Rhodococcus rhodochrous* DSM 43241^T^ as the outgroup. Numbers at nodes indicate levels of bootstrap support (%) based on a neighbor-joining analysis of 1000 resampled datasets. NCBI accession numbers are given. Bar, 0.01 nucleotide substitutions per site

HPLC analysis of crude extracts from XJ13 fermentation broth supernatant revealed an apparently diverse profile of natural product compounds (Fig. [3A](#Fig3){ref-type="fig"}). Using the fractionation scheme detailed in the "[Materials and methods](#Sec2){ref-type="sec"}" section, multiple compounds were purified, and subsequent anti-BCG bioassay-guided isolation led to the isolation of two benz\[α\]anthraquinones, brasiliquinones D (**13**) and E (**14**) (Fig. [3B](#Fig3){ref-type="fig"}). Furthermore, siderophores detected in fraction 8 were chelated with Ga^3+^ prior to purification. The iron complex of siderophores is typically stable and easy for separation; however, the ferric iron present in ferric siderophore exists in a paramagnetic high spin d^5^ state which causes severe line broadening of the NMR signals. Thus, Ga^3+^ or the Al^3+^ siderophore complexes are usually employed for NMR experiments (Jalal and van der Helm [@CR21]). A 10-fold excess of GaBr~3~ was added into fraction 8 and clearly separated peaks were apparent in HPLC analyses of siderophore-containing fractions (Fig. [4A](#Fig4){ref-type="fig"}). Meanwhile, a metal-to-ligand charge transfer band at *λ*~max~ = 340 nm (Seyedsayamdost et al. [@CR48]) was observed (Fig. [4C](#Fig4){ref-type="fig"}), compared with the band at *λ*~max~ = 308 nm for Ga^3+^ free-siderophores (Fig. [4B](#Fig4){ref-type="fig"}). After chelation with GaBr~3~, twelve Ga-siderophores complexes (**1a**−**12a**) were subsequently purified and used for acquisition of NMR spectra, which allowed the structural elucidation of nocardimicins B, D, F, and J\~R (**1**−**12**) (Fig. [3B](#Fig3){ref-type="fig"}). Among these identified siderophores, **4**−**12** and **14** are previously unreported structures.Fig. 3HPLC-UV profiles of crude extracts of strain XJ31 cultured in medium (A). Noc05 and structures of isolated compounds (1−14) (B)Fig. 4HPLC profiles of siderophores-containing fraction (upper panel of A) and chelation with GaBr~3~ (lower panel of A). UV spectra of siderophores (B) and their Ga^3+^ complexes (C)

Compound **4a** was isolated as a white powder. The molecular formula was deduced as C~40~H~58~N~5~O~10~Ga based on HR-ESI-MS data (Fig. [S4a](#MOESM1){ref-type="media"}) (*m/z* 838.3530 \[M + H\]^+^, calcd. for 838.3512) with 13 degrees of unsaturation. Combined analysis of ^1^H NMR, ^13^C NMR, and HSQC spectra (Figs. [S4b--S4d](#MOESM1){ref-type="media"}) of **4a** indicated the presence of two amide protons (*δ*~H~ 10.11 and 7.94), a 1,2-disubstituted benzene moiety (*δ*~C~/*δ*~H~ 167.6, 135.4/7.39, 128.1/8.01, 123.4/7.30, 117.0/6.79, and 112.5), three methyl groups (*δ*~C~/*δ*~H~ 17.2/1.35, 14.8/0.88, and 10.1/1.03), five carbonyl carbons (*δ*~C~ 172.2, 171.9, 166.8, 163.9, and 159.9), three additional aromatic carbons (*δ*~C~ 166.3, 143.2, and 136.4), one oxymethine (*δ*~C~/*δ*~H~ 78.1/5.36), two nitrogen-bearing methylenes (*δ*~C~/*δ*~H~ 53.5/3.45 and 49.3/4.00), two nitrogen-bearing methine (*δ*~C~/*δ*~H~ 55.7/4.83 and 45.8/2.95), 17 methylenes, and one methine (Table [S4](#MOESM1){ref-type="media"}). These data revealed that **4a** had a nocardimicin-type framework, by comparison with those of previously reported compounds (Ikeda et al. [@CR20]).

The ^1^H-^1^H COSY and HMBC experiments (Figs. [S4e and S4f](#MOESM1){ref-type="media"}) of **4a** revealed four sub-structures A\~D shown in Fig. [5](#Fig5){ref-type="fig"}: a hydroxyphenyloxazoline, a fatty acid moiety, and two lysine-derived moieties. The sub-structure A was determined by HMBC correlations from H-3 to C-1 and C-5, from H-6 to C-2, C-4, and C-7, and from H-9 to C-7, C-10, and C-12. The proton spin systems of sub-structure B could be determined by COSY correlations of H-13/H-14, H-14/H-28b, H-28/H-29, H-29a/H-30b, and H-30/H-31 and correlation of H-34/H-52. HMBC correlations from ε-methylene proton H-31 and a triplet methyl proton H-52 to C-33 indicated the presence of a propanoyl group at N-32. The sub-structure B was thus determined as *N*~ε~-propanoyllysine. Sub-structure C was elucidated as 2-methyl-3-hydroxytetradecanoid acid according to the COSY correlations shown in blue color, together with HMBC correlations from H-17 and H-54 to C-19. Sub-structure D was deduced from HMBC correlations of H-21/C-22, H-20/C-22, and H-24/C-22.Fig. 5Key COSY and HMBC correlations for compounds **4** and **14**

The organization of the sub-structures was determined based on HMBC experiments (Fig. [S4f](#MOESM1){ref-type="media"}). The relationship of sub-structures A and B was confirmed by HMBC correlation from H-13 to C-12. The connectivity of sub-structures B and C was established by the HMBC correlation of H-17/C-15 through an ester bond. The HMBC correlations from H-20 and H-21 to C-19 indicated the linkage of the sub-structures C and D through an amide bond. Based on molecular formula of **4a**, the remaining two hydroxyl groups were assigned as substituents at the nitrogen atoms N-23 and N-32. All of the signals in the 2D NMR spectra were assigned unambiguously (Table [S4](#MOESM1){ref-type="media"}). These data supported the structure assigned to nocardimicin J (**4**) (Fig. [3](#Fig3){ref-type="fig"}), the Ga^3+^ free form of **4a**.

The molecular formulae of Ga^3+^-chelated nocardimicins L (**6a**), N (**8a**), and Q (**11a**) were deduced as C~42~H~62~N~5~O~10~Ga, C~44~H~66~N~5~O~10~Ga, and C~46~H~70~N~5~O~10~Ga, respectively, according to their HR-ESI-MS (\[M + H\]^+^ *m/z* 866.3836, 894.4152, and 922.4458) (Figs. [S6a, S8a, and S11a](#MOESM1){ref-type="media"}). ^1^H and ^13^C NMR data of these compounds (Figs. [S6b, S6c, S8b, S8c, S11b, and S11c](#MOESM1){ref-type="media"}) were very similar to those of **4a**. The ion mass of **6a** was 28 mass units (C~2~H~4~) larger than that of **4a**; the mass of **8a** was 56 mass units (C~4~H~8~) larger than **4a**, and that of **11a** was 84 mass units (C~6~H~12~) larger than **4a**. These data indicated that these compounds were the analogs of **4a** differing in their fatty acid chain lengths. All of the signals in the 2D NMR spectra of these compounds were assigned unambiguously (Figs. [S6d--S6f, S8d--S8f, and S11d--S11f](#MOESM1){ref-type="media"}; Tables [S6, S8, and S11](#MOESM1){ref-type="media"}). Based on these data, the structures of the Ga^3+^ free form of **6a**, **8a**, and **11a** were determined as nocardimicins L (**6**), N (**8**), and Q (**11**) (Fig. [3](#Fig3){ref-type="fig"}).

Compound **5a** was isolated as a white powder. The molecular formula was determined to be C~41~H~60~N~5~O~10~Ga based on HR-ESI-MS (Fig. [S5a](#MOESM1){ref-type="media"}) (*m/z* 852.3677 \[M + H\]^+^, calcd. for 852.3669) with 13 degrees of unsaturation. ^1^H and ^13^C NMR data (Figs. [S5b and S5c](#MOESM1){ref-type="media"}) of **5a** were very similar to those of **4a**, except the presence of an extra methylene group (*δ*~C~/*δ*~H~ 19.4/1.66-1.56). The COSY (Fig. [S5d](#MOESM1){ref-type="media"}) correlations of H-34/H-52 and H-52/H-53 revealed the existence of propyl group. The HMBC (Fig. [S5f](#MOESM1){ref-type="media"}) correlations of H-34/C-33, H-34/C-52, H-52/C-33, H-52/C-53, H-53/C-34, and H-53/C-52 indicated the attachment of a butanoyl group at N-32 of the lysine unit. Thus, the structure of the Ga^3+^ free form of **5a** was analyzed *via* 2D NMR spectra (Figs. [S5d--S5f](#MOESM1){ref-type="media"}; Table [S5](#MOESM1){ref-type="media"}), and it was determined to be nocardimicin K (**5**) (Fig. [3](#Fig3){ref-type="fig"}). The ^1^H and ^13^C NMR data for **7a**, **9a**, and **12a** (Figs. [S7b, S7c, S9b, S9c, S12b, and S12c](#MOESM1){ref-type="media"}) were very similar to those of **5a**: their HR-ESI-MS spectra indicated that these compounds are analogs of **5a** differing in their fatty acid chain lengths. The molecular formulae of **7a**, **9a**, and **12a** were determined to be C~43~H~64~N~5~O~10~Ga, C~45~H~68~N~5~O~10~Ga, and C~47~H~72~N~5~O~10~Ga, respectively, according to their HR-ESI-MS data (\[M + H\]^+^ *m/z* 880.3991, 908.4299, and 936.4622) (Figs. [S7a, S9a, and S12a](#MOESM1){ref-type="media"}). The ion mass of **7a** was 28 mass units (C~2~H~4~) larger than that of **5a**, that of **9a** was 56 mass units (C~4~H~8~) larger, and that of **12a** was 84 mass units (C~6~H~12~) larger. All of the signals in 2D NMR spectra of these compounds were assigned unambiguously (Figs. [S7d--S7f, S9d--S9f, and S12d--S12f](#MOESM1){ref-type="media"}; Tables [S7, S9, and S12](#MOESM1){ref-type="media"}). Based on these data, the structures of the Ga^3+^ free forms of **7a**, **9a**, and **12a** were determined as nocardimicins M (**7**), O (**9**), and R (**12**) (Fig. [3](#Fig3){ref-type="fig"}).

Compound **10a** was isolated as a white powder. The molecular formula was determined to be C~45~H~68~N~5~O~10~Ga based on HR-ESI-MS (Fig. [S10a](#MOESM1){ref-type="media"}) (*m/z* 908.4301 \[M + H\]^+^, calcd. for 908.4295) with 13 degrees of unsaturation. ^1^H and ^13^C NMR data of **10a** (Figs. [S10b and S10c](#MOESM1){ref-type="media"}) were very similar to those of **11a**, except for the absence of a methylene group. The HMBC (Fig. [S10f](#MOESM1){ref-type="media"}) correlation between the methyl group CH~3~-34 (*δ*~C~/*δ*~H~ 16.8/2.03) and the carbonyl group (C-33) indicated attachment of an acetyl group at N-32 of the lysine unit. Thus, the structure of the Ga^3+^ free form of **10a** was determined to be nocardimicin P (**10**) (Figs. [3](#Fig3){ref-type="fig"}, [S10d, and S10e](#MOESM1){ref-type="media"}; Table [S10](#MOESM1){ref-type="media"}).

The structures of the three known siderophores, nocardimicin B (**1**), nocardimicin D (**2**), nocardimicin F (**3**), were determined based on the HR-ESI-MS, ^1^H NMR, and ^13^C NMR data of their Ga^3+^-chelated products **1a**, **2a**, and **3a** (Figs. [S1--S3](#MOESM1){ref-type="media"}), respectively, and by comparison with those of previous reports (Ikeda et al. [@CR20]).

Compound **13** was obtained as a yellow amorphous powder. The molecular formula of **13** was established as C~28~H~29~NO~8~ on the basis of its HR-ESI-MS data (*m/z* 508.1978 \[M + H\]^+^, calcd. for 508.1966) (Fig. [S13a](#MOESM1){ref-type="media"}). Compound **13** was determined to be brasiliquinone D according to combined analysis of its UV, ^1^H NMR, and ^13^C NMR spectra (Figs. [S13b-S13d](#MOESM1){ref-type="media"}; Table [S13](#MOESM1){ref-type="media"}) and *via* comparison with previously reported data (Tsuda et al. [@CR56]).

Compound **14** was obtained as a yellow amorphous powder and its molecular formula of **14** was deduced as C~27~H~27~NO~8~ on the basis of HR-ESI-MS data (*m/z* 494.1828 \[M + H\]^+^, calcd. for 494.1809) (Fig. [S14a](#MOESM1){ref-type="media"}). The UV spectrum of **14** (Fig. [S14b](#MOESM1){ref-type="media"}) was identical to that of **13**, a finding indicating that these compounds both share the same benz\[α\]anthraquinone skeleton. The molecular mass of **14** was 14 mass units smaller than that of **13**, indicating a difference of one CH~2~ in their structures. The ^1^H and ^13^C NMR data (Figs. [S14c and S14d](#MOESM1){ref-type="media"}) of **14** were similar to those of **13**, except the absence of a CH~2~ group (*δ*~C~/*δ*~H~ 29.0/1.53). The structure of **14** was analyzed *via* 2D NMR (Figs. [5](#Fig5){ref-type="fig"} and [S14e-S14g](#MOESM1){ref-type="media"}; Tables [1](#Tab1){ref-type="table"} and [S14](#MOESM1){ref-type="media"}) and was determined to be the previously unreported compound brasiliquinone E.Table 1NMR data (500 MHz for ^1^H NMR and 125 MHz for ^13^C NMR, CD~3~OD) for Brasiliquinone E (**14**)Pos.*δ*~C~*δ*~H~, mult (*J* in Hz)COSYHMBC1200.3249.12.83, dd (15.5, 4.7)2b, 312.53, m31, 3, 13331.92.38, m439.23.02, dd (16.7, 3.9)3, 4b4a, 12b2.7, dd (16.7, 10.6)32, 3, 4a, 5, 12b, 134a154.65122.17.08, s4, 6, 6a, 12b6164.86a119.07190.27a122.18158.49121.77.75, d (9.0)101110137.87.83, t (8.0)9, 118, 11a11121.27.73, d (7.7)108, 1211a138.812185.612a139.012b129.31321.61.18, d (6.6)2, 3, 41′96.85.97, d (3.2)2′a3′, 5′2′34.42.35, m2′b2.22, dd (15.0, 1.4)1′, 3′, 4′3′47.44.65, m2′a, 4′4′73.73.52, dd (10.0, 4.3)5′, 6′5′66.93.83, m4′, 6′6′18.11.19, d (6.2)4′, 5′3′-NAc174.53′-NAc23.42.25, s3′-NAc

The anti-BCG activity of the isolated compounds was evaluated, and the two benz\[α\]anthraquinones **13** and **14** both showed potent activity against BCG, with MIC values of around 25 μM.

Discussion {#Sec11}
==========

From the late 1940s to 1960s, many new antibiotics were isolated from actinobacteria during the Golden Age of antibiotic discovery. Approximately 60% of these antibiotics were discovered from the genus *Streptomyces* (Bérdy [@CR4]). More recently, there has been extensive overlap in the reported compounds isolated from *Streptomyces* species, a situation which has guided research attention away from this taxon and towards non-*Streptomyces* actinobacteria, which are sometimes referred to as "rare actinobacteria" (Subramani and Aalbersberg [@CR50]; Subramani and Sipkema [@CR51]). Unexplored (and underexplored) ecological environments are promising sources for the discovery of rare actinobacteria, and these organisms are believed to be rich sources for structurally diverse, yet unknown, compounds (Dhakal et al. [@CR13]).

Xinjiang area harbors lots of highly diversified ecological environments, including salt lakes, deserts, and plateaus with saline-alkali soils. Our previous efforts to isolate rare actinobacteria from extreme environments such as work in the South China Sea and a Xinjiang desert have successfully described a series of new species from genera including *Verrucosispora* and *Prauserella* (Dai et al. [@CR12]; Liu et al. [@CR31]; Wang et al. [@CR57], [@CR58]). In the present study, we continued a survey of the biological diversity of actinobacteria from the Xinjiang region and explored the potential anti-TB activity of NPs present in previously unknown strains. Using a selective isolation method, 40 rare actinobacteria belonging to eight genera were isolated from 17 samples collected in Xinjiang region. Among these rare genera, *Micromonospora* and *Nocardia* were dominant, representing 49% and 26% of the strains, respectively.

Further phylogenetic analysis based on 16S rRNA gene sequences emphasized the rarity of an actinomycete strain which we deemed *Nocardia* sp. XJ31 and that showed the highest similarity to *N. goodfellowii* (97.81%). The natural product profile of XJ31 was evaluated using an OSMAC approach. Two classes of NPs, siderophores (**1**−**12**) and anthraquinones (**13** and **14**), were thusly identified from strain XJ31 fermentation extracts, including ten new compounds (nocardimicins J−R and brasiliquinone E).

According to earlier reports, nearly 40% of anti-mycobacterial compounds have been isolated from genera including *Amycolatopsis*, *Nocardia*, *Actinomadura*, *Bacillus*, *Pleurotus*, and *Saccharopolyspora*, all of which are similar to *Mycobacterium* strains (Ashforth et al. [@CR3]; Butler and Buss [@CR7]). Mukai et al. ([@CR38]) reported that a novel thiopeptide nocardithiocin, isolated from the pathogenic *N. pseudobrasiliensis* strain IFM 0757, was highly active against rifampicin-resistant as well as rifampicin-sensitive TB strains, exhibiting a range of MIC values from 0.025 to 1.56 μg/mL. Our findings in the present study revealed that two anthraquinones, brasiliquinones D (**13**) and E (**14**), showed moderate anti-BCG activity (MIC = 25 μM). Brasiliquinones were originally discovered from *Nocardia brasiliensis* by Tsuda et al. ([@CR55]). Brasiliquinone A−C exhibited anti-bacterial activity against *M. smegmatis*, in agreement with anti-BCG activity of brasiliquinone E in this study. The inspiration of looking for novel natural products with anti-TB activity was driven by the fact that the multi-drug resistance tuberculosis (MDR-TB) is rising with the current treatment such as isoniazid (MIC = 1.4 μM) and rifampin (MIC = 0.3 μM) (Lee and Heifets [@CR27]). Although brasiliquinones do not have comparable activity as indicated by MIC level, they still represent potential application value considering the drug resistance issue.

Nocardimicins A−F were discovered from *Nocardia* sp. TP-A0674 in the screening for muscarinic M3 receptor--binding inhibitors (Ikeda et al. [@CR20]); thus, they are identified as potential candidates for neurotransmission disorder treatment. There has no reported anti-bacterial activity with nocardimicins, neither nocardimicins A−J exhibited inhibitory activity on BCG, MRSA, *S. aureus*, and *B. subtilis* (data not shown) analyzed with our inhouse bioassay. Besides, it is well known that iron is one of the major limiting factors and essential nutrients of microbial life (Litwin and Calderwood [@CR28]). The nocardimicins represent the bulk of the NPs produced in *Nocardia* sp. XJ31; thus, the high yield could be the bacteria's response to the environment stress.

In nature, microorganisms produce small, high-affinity chelating molecules referred to as siderophores to facilitate their acquisition of iron (Saha et al. [@CR46]). There are three types of siderophores, i.e., hydroxamates, catecholates, and carboxylates (Ali and Vidhale [@CR1]). These molecules have been widely used in agricultural (Chaiharn et al. [@CR9]), environmental (Ruggiero et al. [@CR45]), and biomedical applications. In agriculture, siderophores have been used as biocontrol agents (Husen [@CR19]), and the biomedical application of these compounds has exploited their anti-cancer (Chua et al. [@CR10]), anti-malarial (Breidbach et al. [@CR6]; Gysin et al. [@CR16]), and anti-infectious (Wooldridge and Williams [@CR61]) activities. Miller et al. ([@CR36]) reported that when conjugated with mycobactin analogs, the anti-malarial agent artemisinin exhibits activity against *M. tuberculosis*. Conjugates of siderophores and antibiotics are called "Trojan horse" antibiotics, in which the antibiotic compound utilizes the siderophores as a mediator for entry into cells *via* the iron-uptake machinery (Möllmann et al. [@CR37]; Ratledge and Dover [@CR44]). Hence, the discovery of new siderophores with antibiotic properties provides valuable materials and insights that can drive drug discovery and development efforts.

In addition, we have performed computer-aided virtual screening on compounds in this study to look for potential viral development inhibitors (supplementary document). Lassa virus polymerase (PDB ID: 6KLC), Machupo virus polymerase (PDB ID: 6KLE), Influenza A virus polymerase (PDB ID: 6QX3), and Influenza D virus polymerase (PDB ID: 6KUJ) are key enzymes for virus replication. Notably, all the isolated compounds were docked onto the active site of 3′-RNA pocket of virus polymerases to evaluate their binding affinities by using Gold program (Jones et al. [@CR23]). Siderophores nocardimicins A−J (**1**−**12**) exhibited significant binding affinities with the four 3'′-RNA pockets of virus polymerases (\> 90%) (Table [S13](#MOESM1){ref-type="media"}). Virus infection severely affected healthy human beings (Peters et al. [@CR42]); especially the emerging outbreak of COVID-2019 caused by SARS-CoV-2 (Zhu et al. [@CR62]) highlights the urgent need of developing broad-spectrum antivirus drugs. Our preliminary data revealed important potentials of these siderophores for broad-spectrum antivirus drug development. Cell-based evaluation of virus polymerases inhibitory effects of these siderophores is ongoing.

This study expands the knowledge about the distribution and biodiversity of rare actinobacteria and their corresponding bioactive chemical entities from diverse environments in Xinjiang. Among the rare actinobacteria genera of our study, the genus *Nocardia* is the second most prevalent, and we show that *Nocardia* sp. XJ31 exerts anti-BCG activity by producing anthraquinone-type compounds. This study offers a strategy to investigate new bioactive compounds from microbes in extreme habitats.
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